Cencora’s third quarter results outperformed Wall Street’s expectations on both revenue and adjusted profit, but the market ...

Cencora delivered strong quarterly results and guidance upgrades, but expectations need to be moderated as these results ...

Cencora, Inc. earns a Buy rating with a $337 fair value. Learn how its specialty drug focus and strategic investments drive ...

Readers hoping to buy Cencora, Inc. (NYSE:COR) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date is one business day before a ...

Cencora COR saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 70 to 78. Please watch ...

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the ...

Q3 2025 Earnings Call Transcript August 6, 2025 Cencora, Inc. beats earnings expectations. Reported EPS is $4, expectations were $3.85. Operator: Hello, everyone, and thank you for joining the Cencora ...

Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Cencora ( (COR)) is now available. On August 6, 2025, Cencora ...

U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped ...

Shares of Cencora Inc. COR shed 2.93% to $283.78 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.73% to 6,345.06 and ...

Shares of Cencora Inc. COR slipped 1.96% to $286.08 Thursday, on what proved to be an all-around rough trading session for ...

TD Cowen analyst Charles Rhyee maintained a Buy rating on Cencora today and set a price target of $350.00. The company’s shares closed yesterday at $283.78. Elevate Your Investi ...